Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy

Jodie F. Hay; Katrina Lappin; Fabio Liberante; Laura M. Kettyle; Kyle B. Matchett; Alexander Thompson; Ken I. Mills

doi:10.18632/oncotarget.18910

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy

Jodie F. Hay, Katrina Lappin, Fabio Liberante, Laura M. Kettyle, Kyle B. Matchett, Alexander Thompson and Ken I. Mills _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:67891-67903. https://doi.org/10.18632/oncotarget.18910

Metrics: PDF 1740 views | HTML 2348 views | ?

Abstract

Jodie F. Hay1,2, Katrina Lappin1, Fabio Liberante1,3, Laura M. Kettyle1,4, Kyle B. Matchett1, Alexander Thompson1,5 and Ken I. Mills1

1Blood Cancer Research Group, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK

2Molecular Oncology Laboratory, MRC – University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, UK

3Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

4Haematopoietic Stem Cell Biology, MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK

5Division of Cancer and Stem Cells, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK

Correspondence to:

Ken I. Mills, email: [email protected]

Keywords: acute myeloid leukaemia, Vorinostat, HDAC, epigenetics

Received: October 15, 2016 Accepted: May 31, 2017 Published: July 01, 2017

ABSTRACT

Several histone deacetylase inhibitors including Vorinostat have received FDA approval for the treatment of haematological malignancies. However, data from these trials indicate that Vorinostat has limited efficacy as a monotherapy, prompting the need for rational design of combination therapies. A number of epi-sensitised pathways, including sonic hedgehog (SHH), were identified in AML cells by integration of global patterns of histone H3 lysine 9 (H3K9) acetylation with transcriptomic analysis following Vorinostat-treatment. Direct targeting of the SHH pathway with SANT-1, following Vorinostat induced epi-sensitisation, resulted in synergistic cell death of AML cells. In addition, xenograft studies demonstrated that combination therapy induced a marked reduction in leukemic burden compared to control or single agents. Together, the data supports epi-sensitisation as a potential component of the strategy for the rational development of combination therapies in AML.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18910

Publication Alerts

Research Papers:

Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy

Abstract